Leerink Presents: Your 2017 Biopharma Catalyst Tracker
March 20, 2017 - 9:17am
In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017.
Celgene — Multiple Readout In 2017
On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts across I&I and oncology in 2017. However, most of the events are back-end loaded, the firm said.
By year-end 2017, the company has many key events, including submission of ozanimod NDA in multiple sclerosis, results of separate late-stage studies on Revlimid in newly diagnosed and R/R FL, Otezla in Behcet's disease and Abraxane in Adjuvant pancreatic cancer. In the second half, the company is expecting Enasidenib in IDH2 + AML.
Alexion — Positioned For Important News In 2017
Leerink believes Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is well positioned for important news in 2017. FDA PDUFA date for Soliris is set for some time in the third quarter and the first Phase III trial results for ALXN 1210 are expected by the end of 2017.
Regeneron Has Critical Events
According to Leerink, critical events for Regeneron Pharmaceuticals Inc (NASDAQ: REGN), include Dupixent approval, label and price. The Dupixent PDUFA date is set for March 29, 2017. The firm expects Kevzara approval in the second quarter. The catalysts scheduled for the second half include Odyssey outcomes, Dupixent asthma pivotals, nesvacumab phase II.
Vertex To Benefit From Disclosures, Risk Reduction
Leerink expects Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to benefit from significant disclosures and risk reduction from its second and third ...Full story available on Benzinga.com
Continue reading this article »